First patient dosed in the pediatric cohort of the Phase 1/2 trial of OPGx-LCA5; initial data on the cohort anticipated by Q3 2025New 12-month data on the first three adult OPGx-LCA5 patients to be pr ...

First patient dosed in the pediatric cohort of the Phase 1/2 trial of OPGx-LCA5; initial data on the cohort anticipated by Q3 2025New 12-month ...

Kodiak Sciences Inc. (NASDAQ:KOD – Get Free Report) was the target of a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling ...